Claims
- 1. A method for treating ulcerative colitis in a human which comprises rectally administering to the human a therapeutically effective amount of monoclonal antibody 7E.sub.12 H.sub.12, which is secreted by hybridoma ATCC HB9397, which binds to a colonic antigen associated with ulcerative colitis.
- 2. The method according to claim 1, wherein the antibody is administered in an amount from about 50 .mu.g/day to about 500 .mu.g/day.
- 3. The method according to claim 1, wherein the colonic antigen is p40.
- 4. The method according to claim 1, wherein the colonic antigen is gp185.
Parent Case Info
This application is a continuation-in-part of parent application Ser. No. 08/437,474, filed May 9, 1995, now abandoned.
Non-Patent Literature Citations (1)
Entry |
Nandiwada et al. (Apr. 1993). Gastroenterol. 104:A754. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
437474 |
May 1995 |
|